Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1-Alpha Mutation Carriers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear factor 1α (HNF1A) diabetes, but SUs have limitations due to risk of hypoglycemia. Treatment based on the incretin hor-mones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by their glucose-dependent insulinotropic actions without risk of hypoglycemia. The effect of SUs together with GIP or GLP-1, respectively, on insulin and glucagon secretion in patients with HNF1A diabetes is currently unknown. To investigate this, 10 HNF1A mutation carriers and 10 control subjects without diabetes were recruited for a double-blinded, placebo-controlled, crossover study including 6 experimental days in a randomized order involving 2-h euglycemic-hyperglycemic clamps with coadministration of: 1) SU (glimepiride 1 mg) or placebo, combined with 2) infusions of GIP (1.5 pmol/kg/min), GLP-1(0.5pmol/kg/min),orsaline(NaCl).InHNF1A mutation carriers, we observed: 1) hypoinsulinemia,2) insulinotropic effects of both GIP and GLP-1, 3) additive to supra-additive effects on insulin secretion when combining SU+GIP and SU+GLP-1, respectively, and 4) increased fasting and arginine-induced glucagon levels compared with control subjects without diabe-tes. Our study suggests that a combination of SU and incretin-based treatment may be efficacious in patients with HNF1A diabetes via potentiation of glucose-stimulated insulin secretion.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind69
Udgave nummer9
Sider (fra-til)1989-2002
Antal sider14
ISSN0012-1797
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

© 2020 by the American Diabetes Association.

ID: 60285948